These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 8446467)

  • 1. Vaccine development against cutaneous leishmaniasis. Subcutaneous administration of radioattenuated parasites protects CBA mice against virulent Leishmania major challenge.
    Rivier D; Shah R; Bovay P; Mauel J
    Parasite Immunol; 1993 Feb; 15(2):75-84. PubMed ID: 8446467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccination against Leishmania major in a CBA mouse model of infection: role of adjuvants and mechanism of protection.
    Rivier D; Bovay P; Shah R; Didisheim S; Mauël J
    Parasite Immunol; 1999 Sep; 21(9):461-73. PubMed ID: 10476055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A radioattenuated Leishmania major vaccine markedly increases the resistance of CBA mice to subsequent infection with Leishmania mexicana mexicana.
    Alexander J
    Trans R Soc Trop Med Hyg; 1982; 76(5):646-9. PubMed ID: 7179418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interferon-gamma-inducing oral vaccination with Leishmania amazonensis antigens protects BALB/c and C57BL/6 mice against cutaneous leishmaniasis.
    Pinto EF; de Mello Cortezia M; Rossi-Bergmann B
    Vaccine; 2003 Sep; 21(25-26):3534-41. PubMed ID: 12922080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protective immunity against the protozoan Leishmania chagasi is induced by subclinical cutaneous infection with virulent but not avirulent organisms.
    Streit JA; Recker TJ; Filho FG; Beverley SM; Wilson ME
    J Immunol; 2001 Feb; 166(3):1921-9. PubMed ID: 11160240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunoregulatory pathways in murine leishmaniasis: different regulatory control during Leishmania mexicana mexicana and Leishmania major infections.
    Alexander J; Kaye PM
    Clin Exp Immunol; 1985 Sep; 61(3):674-82. PubMed ID: 3907906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a safe live Leishmania vaccine line by gene replacement.
    Titus RG; Gueiros-Filho FJ; de Freitas LA; Beverley SM
    Proc Natl Acad Sci U S A; 1995 Oct; 92(22):10267-71. PubMed ID: 7479765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The potency and durability of DNA- and protein-based vaccines against Leishmania major evaluated using low-dose, intradermal challenge.
    Méndez S; Gurunathan S; Kamhawi S; Belkaid Y; Moga MA; Skeiky YA; Campos-Neto A; Reed S; Seder RA; Sacks D
    J Immunol; 2001 Apr; 166(8):5122-8. PubMed ID: 11290794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccination with the Leishmania infantum acidic ribosomal P0 protein plus CpG oligodeoxynucleotides induces protection against cutaneous leishmaniasis in C57BL/6 mice but does not prevent progressive disease in BALB/c mice.
    Iborra S; Carrión J; Anderson C; Alonso C; Sacks D; Soto M
    Infect Immun; 2005 Sep; 73(9):5842-52. PubMed ID: 16113303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Leishmania tropica: suggestive evidences for the effect of infectious dose on pathogenicity and immunogenicity in an experimental model.
    Rostamian M; Jafari D; Abolghazi M; Farahani H; Niknam HM
    Parasitol Res; 2018 Sep; 117(9):2949-2956. PubMed ID: 29978420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccination with a Leishmania infantum HSP70-II null mutant confers long-term protective immunity against Leishmania major infection in two mice models.
    Solana JC; Ramírez L; Corvo L; de Oliveira CI; Barral-Netto M; Requena JM; Iborra S; Soto M
    PLoS Negl Trop Dis; 2017 May; 11(5):e0005644. PubMed ID: 28558043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous injection of irradiated Leishmania major into susceptible BALB/c mice: immunization or protective tolerance.
    Aebischer T; Morris L; Handman E
    Int Immunol; 1994 Oct; 6(10):1535-43. PubMed ID: 7826944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccination with phosphoglycan-deficient Leishmania major protects highly susceptible mice from virulent challenge without inducing a strong Th1 response.
    Uzonna JE; Späth GF; Beverley SM; Scott P
    J Immunol; 2004 Mar; 172(6):3793-7. PubMed ID: 15004184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral immunization using live Lactococcus lactis co-expressing LACK and IL-12 protects BALB/c mice against Leishmania major infection.
    Hugentobler F; Di Roberto RB; Gillard J; Cousineau B
    Vaccine; 2012 Aug; 30(39):5726-32. PubMed ID: 22814408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccination against cutaneous leishmaniasis in mice using nonpathogenic cloned promastigotes of Leishmania major and importance of route of injection.
    Mitchell GF; Handman E; Spithill TW
    Aust J Exp Biol Med Sci; 1984 Apr; 62 ( Pt 2)():145-53. PubMed ID: 6466205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Testing of four Leishmania vaccine candidates in a mouse model of infection with Leishmania (Viannia) braziliensis, the main causative agent of cutaneous leishmaniasis in the New World.
    Salay G; Dorta ML; Santos NM; Mortara RA; Brodskyn C; Oliveira CI; Barbiéri CL; Rodrigues MM
    Clin Vaccine Immunol; 2007 Sep; 14(9):1173-81. PubMed ID: 17626159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intradermal inoculations of low doses of Leishmania major and Leishmania amazonensis metacyclic promastigotes induce different immunoparasitic processes and status of protection in BALB/c mice.
    Courret N; Lang T; Milon G; Antoine JC
    Int J Parasitol; 2003 Oct; 33(12):1373-83. PubMed ID: 14527520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccine-induced protection against Leishmania amazonensis is obtained in the absence of IL-12/23p40.
    Hernández MX; Barçante TA; Vilela L; Tafuri WL; Afonso LC; Vieira LQ
    Immunol Lett; 2006 May; 105(1):38-47. PubMed ID: 16466810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Study of the safety, immunogenicity and efficacy of attenuated and killed Leishmania (Leishmania) major vaccines in a rhesus monkey (Macaca mulatta) model of the human disease.
    Amaral VF; Teva A; Oliveira-Neto MP; Silva AJ; Pereira MS; Cupolillo E; Porrozzi R; Coutinho SG; Pirmez C; Beverley SM; Grimaldi G
    Mem Inst Oswaldo Cruz; 2002 Oct; 97(7):1041-8. PubMed ID: 12471434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Leishmania pifanoi amastigote antigens protect mice against cutaneous leishmaniasis.
    Soong L; Duboise SM; Kima P; McMahon-Pratt D
    Infect Immun; 1995 Sep; 63(9):3559-66. PubMed ID: 7642292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.